Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 'Living Drug' trial offers hope for lymphoma patients out of options

NCT ID NCT06544265

Recruiting now Disease control Sponsor: Verismo Therapeutics Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goals are to find a safe dose and see if the treatment is feasible and shows signs of fighting the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rutgers Cancer Institute

    RECRUITING

    New Brunswick, New Jersey, 08902, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The University of Kansas Cancer Center

    RECRUITING

    Fairway, Kansas, 66205, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship Cancer Institute of Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA B CELL LYMPHOMA DIFFUSE LARGE B CELL LYMPHOMA DLBCL DLBCL (DIFFUSE LARGE B-CELL LYMPHOMA) ASSOCIATED WITH CHRONIC INFLAMMATION DLBCL - DIFFUSE LARGE B CELL LYMPHOMA EPSTEIN-BARR VIRUS POSITIVE DLBCL, NOS FOLLICULAR LYMPHOMA FOLLICULAR LYMPHOMA GRADE 3 FOLLICULAR LYMPHOMA GRADE 3B HGBL WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED HIGH-GRADE B-CELL LYMPHOMA INDOLENT B-CELL NON-HODGKIN LYMPHOMA LARGE B-CELL LYMPHOMA MANTLE-CELL LYMPHOMA MARGINAL ZONE LYMPHOMA MARGINAL ZONE SPLENIC LYMPHOMA NHL, ADULT NON-HODGKIN LYMPHOMA,B CELL PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) REFRACTORY NON-HODGKIN LYMPHOMA RELAPSED NON HODGKIN LYMPHOMA T-CELL/HISTIOCYTE RICH LYMPHOMA